

Imbruvica (Tablet) - (140,560 mg; Tablet)

| | | | |
|------------------------------|---|-----------------------------|---------------------|
| Generic Name | IBRUTINIB | Innovator | Pharmacyclics |
| Dosage | 140,560 mg; Tablet | Branded US Sales | More Than \$1000 mn |
| Probable FTF | Less Than 5 | Known Para IV Filers | Less Than 5 |
| Other ANDA developers | More Than 5 | Tentative Approvals | Less Than 5 |
| Final Approvals | None | Generic Launches | None |
| Indication | Used to treat certain cancers (such as mantle cell lymphoma, chronic lymphocytic leukemia, Waldenstrom's macroglobulinemia) | | |
| Complexities | Yes | | |

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Imbruvica (Tablet) - (280,420 mg; Tablet, Oral)

| | | | |
|------------------------------|--|-----------------------------|---------------------|
| Generic Name | IBRUTINIB | Innovator | Pharmacyclics |
| Dosage | 280,420 mg; Tablet, Oral | Branded US Sales | More Than \$1000 mn |
| Probable FTF | Less Than 5 | Known Para IV Filers | Less Than 5 |
| Other ANDA developers | More Than 5 | Tentative Approvals | Less Than 5 |
| Final Approvals | None | Generic Launches | None |
| Indication | IMBRUVICA® (ibrutinib) is a prescription medicine used to treat adults with: Mantle cell lymphoma (MCL) who have received at least one prior treatment. Chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL) Chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL) with 17p deletion. | | |
| Complexities | Yes | | |

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.